CA2366877A1 - Composes chimiques et leurs applications - Google Patents

Composes chimiques et leurs applications Download PDF

Info

Publication number
CA2366877A1
CA2366877A1 CA002366877A CA2366877A CA2366877A1 CA 2366877 A1 CA2366877 A1 CA 2366877A1 CA 002366877 A CA002366877 A CA 002366877A CA 2366877 A CA2366877 A CA 2366877A CA 2366877 A1 CA2366877 A1 CA 2366877A1
Authority
CA
Canada
Prior art keywords
compound
substituted
unsubstituted
disorders
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002366877A
Other languages
English (en)
Inventor
Stanley Michael Roberts
Maria Gabriella Santoro
Thierry Guyot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charterhouse Therapeutics Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906587.2A external-priority patent/GB9906587D0/en
Application filed by Individual filed Critical Individual
Publication of CA2366877A1 publication Critical patent/CA2366877A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Animal Husbandry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Insects & Arthropods (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)

Abstract

Des 4- et 5-oxacyclopent-2-en-1-ones font montre d'un activité significative en activant HSF et en inhibant NF-~B. L'on estime qu'ils se révéleront des plus utiles pour traiter une large gamme d'états pathologiques, au nombre desquels, des états pathologiques provoqués par des virus et par des bactéries, des états pathologiques déclenchés par un rayonnement (par exemple. par le rayonnement ultraviolet), des maladies inflammatoires, des maladies du système immunitaire, l'ischémie, l'artériosclérose, des maladies à prolifération cellulaire (des cancers notamment), des maladies entraînant des dommages aux cellules ou provoquant leur mort (par exemple, altérations cellulaire due à des oxydants) et le diabète.
CA002366877A 1999-03-22 2000-03-22 Composes chimiques et leurs applications Abandoned CA2366877A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9906587.2 1999-03-22
GBGB9906587.2A GB9906587D0 (en) 1999-03-22 1999-03-22 Chemical compounds and their uses
US12696899P 1999-03-30 1999-03-30
US60/126,968 1999-03-30
PCT/GB2000/001086 WO2000056341A1 (fr) 1999-03-22 2000-03-22 Composés chimiques et leurs applications

Publications (1)

Publication Number Publication Date
CA2366877A1 true CA2366877A1 (fr) 2000-09-28

Family

ID=26315321

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002366877A Abandoned CA2366877A1 (fr) 1999-03-22 2000-03-22 Composes chimiques et leurs applications

Country Status (7)

Country Link
EP (1) EP1165092A1 (fr)
JP (1) JP2002539264A (fr)
AU (1) AU3665700A (fr)
CA (1) CA2366877A1 (fr)
HK (1) HK1041200A1 (fr)
NZ (1) NZ514522A (fr)
WO (1) WO2000056341A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7933298A (en) * 1997-06-27 1999-01-19 Kaneka Corporation Heat shock factor activity inhibitors
JP2005511775A (ja) * 2001-12-14 2005-04-28 チャーターハウス セラピューティックス リミテッド 医薬組成物の改良
AU2002352402A1 (en) * 2001-12-14 2003-06-30 Charterhouse Therapeutics Limited Improvements in pharmaceutical compositions
GB0218261D0 (en) * 2002-08-06 2002-09-11 Charterhouse Therapeutics Ltd Improvements in pharmaceutically useful compounds
CA2495068A1 (fr) * 2002-08-14 2004-02-26 Janssen Pharmaceutica N.V. Utilisation d'inhibiteurs du nf-kappa b pour le traitement de la mastite
CA2692004C (fr) 2007-06-15 2013-04-09 Board Of Regents, The University Of Texas System Procedes et compositions pour inhiber le facteur d'oedeme et l'adenylylcyclase
US9101601B2 (en) 2012-01-09 2015-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing insulin resistance and associated diseases and conditions
CA2891294A1 (fr) 2012-11-15 2014-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methodes de traitement de patients infectes par le vih et le htlv
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3375914D1 (en) * 1982-10-07 1988-04-14 Teijin Ltd Novel 5-membered cyclic compounds, process for the production thereof, and pharmaceutical use thereof
DE3586085D1 (de) * 1984-10-22 1992-06-25 Teijin Ltd Antitumor-4-hydroxy-2-zyklopentenonen.
JPS6244A (ja) * 1985-06-25 1987-01-06 Nippon Iyakuhin Kogyo Kk ２−ハロ−２−シクロペンテノン誘導体及びその製法
US5216183A (en) * 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
JPH07233142A (ja) * 1994-02-23 1995-09-05 Teijin Ltd ２，３，４，４，５―五置換―２―シクロペンテノン類の製造法
GB9418762D0 (en) * 1994-09-16 1994-11-02 Bayer Ag Use of substituted cyclopentane-DI-and-triones
IT1289250B1 (it) * 1996-12-13 1998-09-29 Consiglio Nazionale Ricerche Impiego di 2 ciclopenten 1-one e suoi derivati come inibitori del fattore nf-kb
IT1284853B1 (it) * 1996-06-18 1998-05-22 Consiglio Nazionale Ricerche Impiego del 2-ciclopenten-1-one come induttore di hsp70.
JP2709807B2 (ja) * 1996-11-01 1998-02-04 富士薬品工業株式会社 ３−クロロ−４−シリルオキシ−２−シクロペンテン−１−オン類の製造法
EA001888B1 (ru) * 1997-03-05 2001-10-22 Такара Сузо Ко., Лтд. Производные циклопентанонов, способ их получения и фармацевтические препараты на их основе
DE69809544T2 (de) * 1997-03-11 2003-10-02 Takara Bio Inc Cyclopentenon-derivate
AU736516B2 (en) * 1997-03-28 2001-07-26 Takara Bio Inc. Therapeutic agent for diabetes mellitus
US6284801B1 (en) * 1997-04-01 2001-09-04 Takara Shuzo Co., Ltd. Antirheumatic agents
EA002354B1 (ru) * 1997-06-30 2002-04-25 Такара Сузо Ко., Лтд. Производные циклопентенона
EA001942B1 (ru) * 1997-07-02 2001-10-22 Такара Сузо Ко., Лтд. Противоаллергические средства
EP1018336A4 (fr) * 1997-07-25 2003-06-18 Takara Bio Inc Carcinostatiques
WO1999029647A1 (fr) * 1997-12-11 1999-06-17 Takara Shuzo Co., Ltd. Inducteurs de l'apoptose

Also Published As

Publication number Publication date
AU3665700A (en) 2000-10-09
WO2000056341A1 (fr) 2000-09-28
EP1165092A1 (fr) 2002-01-02
JP2002539264A (ja) 2002-11-19
HK1041200A1 (zh) 2002-07-05
NZ514522A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
JP2001511770A (ja) インフルエンザ感染の治療用化合物及びそれらの組み合わせ
CA2366877A1 (fr) Composes chimiques et leurs applications
JP2009544577A (ja) 化合物
WO2012140504A1 (fr) Composés thérapeutiques
CN101434517B (zh) 治疗免疫疾病的1，2-二苯基乙烯衍生物
JP2003516995A (ja) シクロペンテンオン誘導体
US7183440B2 (en) Pharmaceutically useful compounds
WO2004013117A1 (fr) Cyclopentanone bicyclique et derives de cyclopentenone en tant qu'activateurs efficaces du facteur de choc thermique (hsf)
US20050124665A1 (en) Pharmaceutical compositions
EP2064170B1 (fr) Derives de cyclohexanone
US4562209A (en) Promotion of feed efficiency in animals
US7759399B2 (en) Pharmaceutical compositions
US20050124696A1 (en) Pharmaceutical compositions
CH641797A5 (fr) Thiophenecarboxamidoalkylmercaptans, utiles notamment comme mucolytiques, et compositions pharmaceutiques les contenant.
CN114502154A (zh) 含苯甲酸酯的组合物治疗神经退行性疾病的用途
US3632775A (en) Method for the treatment of gasterophilus intestinalis
UA139437U (uk) Гідразони ментону та феноксіоцтових кислот з протисудомною дією
JP2018002681A (ja) 医薬組成物

Legal Events

Date Code Title Description
FZDE Discontinued